Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Role of Oligoadenylate Synthetases in Myeloid Neoplasia

Metis Hasipek, PhD, Yihong Guan, PhD, Dale Grabowski, BS, Xiaorong Gu, PhD, Yogenthiran Saunthararajah, MD, Robert Silverman, PhD, George R Stark, PhD, Jaroslaw Maciejewski, PhD, Babal K. Jha, PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142457

Published: 2020

Journal Articles

Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms

Simona Pagliuca, MD, Yihong Guan, PhD, Anand D. Tiwari, PhD, Dale Grabowski, BS, Carmelo Gurnari, MD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, MD, Metis Hasipek, PhD, Laila Terkawi, Misam Zawit, MBBS, Hassan Awada, MD, Valeria Visconte, PhD, Yogenthiran Saunthararajah, MD, James G Phillips, PhD, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-143094

Published: 2020

Journal Articles

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

Nathan Radakovich, BA, David A. Sallman, MD, Rena J. Buckstein, MD FRCPC, Andrew M. Brunner, MD, Sudipto Mukherjee, MD PhD MPH, Rami Komrokji, MD, Najla Al Ali, M.Sc, Jacob Shreve, MD MS, Yazan Rouphail, Cassandra M Kerr, MS, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-139815

Published: 2020

Journal Articles

TET2 Inhibitory Effects of Eltrombopag Contribute Its Hematopoietic Activity

Yihong Guan, PhD, Metis Hasipek, PhD, Bhumika J. Patel, MD, Dale Grabowski, BS, Anand D. Tiwari, PhD, Sunisa Kongkiatkamon, MD, Cassandra M Kerr, MS, Aziz Nazha, MD, Yogenthiran Saunthararajah, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-142875

Published: 2020

Journal Articles

A Novel Therapeutic Strategy for Preferential Elimination of Multiple Myeloma Cells By Targeting Protein Disulfide Isomerase

Metis Hasipek, PhD, Dale Grabowski, BS, Yihong Guan, PhD, Anand D. Tiwari, PhD, Xiaorong Gu, PhD, Jason Valent, MD, Jaroslaw Maciejewski, PhD, Frederic Joel Reu, James G Phillips, PhD, Babal K. Jha, PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-142847

Published: 2020

Journal Articles

Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion

Yihong Guan, PhD, Bhumika J. Patel, MD, Metis Hasipek, PhD, Dale Grabowski, BS, Hassan Awada, MD, Cassandra M Kerr, MS, Valeria Visconte, PhD, Aziz Nazha, MD, Yogenthiran Saunthararajah, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 453.

https://doi.org/10.1182/blood-2019-131525

Published: 2019

Journal Articles

Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)

Nathan Radakovich, BA, Mikkael A. Sekeres, MD MS, Cameron Beau Hilton, BA, Sudipto Mukherjee, MD PhD MPH, Jacob Shreve, MD MS, Yazan Rouphail, Rachel Shirley, Vera Adema, PhD, Hassan Awada, MD, Anjali S. Advani, MD, Cassandra M Kerr, MS, Yasunobu Nagata, MD PhD, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Aziz Nazha, MD

Blood (2019) 134 (Supplement_1): 2089.

https://doi.org/10.1182/blood-2019-126275

Published: 2019

Journal Articles

Fatty Acid Binding Protein FABP5: A Novel Therapeutic Target in Acute Myeloid Leukemia

Metis Hasipek, PhD, Yihong Guan, PhD, Dale Grabowski, BS, Jaroslaw P. Maciejewski, MD PhD, Hetty E. Carraway, MD MBA, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 2553.

https://doi.org/10.1182/blood-2019-130475

Published: 2019

Journal Articles

TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia

Yihong Guan, PhD, Anand D. Tiwari, PhD, James G Phillips, PhD, Metis Hasipek, PhD, Dale Grabowski, BS, Cassandra M Kerr, MS, Vera Adema, PhD, Yasunobu Nagata, MD PhD, Valeria Visconte, PhD, Tomas Radivoyevitch, PhD, Daniel Lindner, MD PhD, Manja Meggendorfer, PhD, Mohamed Abazeed, Mikkael A. Sekeres, MD MS, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 880.

https://doi.org/10.1182/blood-2019-131920

Published: 2019

Journal Articles

Targeting NAD + Modulating Enzymes to Improve HSC Function in Aging and Bone Marrow Failure

Phillip J Maciejewski, Yihong Guan, Metis Hasipek, PhD, Anand D. Tiwari, PhD, Dale Grabowski, BS, James G Phillips, PhD, Yogenthiran Saunthararajah, MD, Jaroslaw P. Maciejewski, Babal K. Jha

Blood (2018) 132 (Supplement 1): 3840.

https://doi.org/10.1182/blood-2018-99-119300

Published: 2018

Journal Articles

Targeting Antagonists of Retinoic Acid Signaling in Acute Myeloid Leukemia

Metis Hasipek, PhD, Dale Grabowski, BS, Yihong Guan, James G Phillips, PhD, Jaroslaw P. Maciejewski, Hetty E. Carraway, MD MBA, Babal K. Jha

Blood (2018) 132 (Supplement 1): 4067.

https://doi.org/10.1182/blood-2018-99-118924

Published: 2018

Journal Articles

Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia

Bhumika J. Patel, MD, Shimoli Vipul Barot, MD, Teodora Kuzmanovic, BA, Bartlomiej P. Przychodzen, Cassandra M. Hirsch, Hassan Awada, MD, Metis Hasipek, PhD, Swapna Thota, MD, Tomas Radivoyevitch, PhD, Anjali S. Advani, MD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 2590.

https://doi.org/10.1182/blood-2018-99-119852

Published: 2018

Journal Articles

Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases

Yihong Guan, Anand D. Tiwari, PhD, Metis Hasipek, PhD, Dale Grabowski, BS, Yvonne Parker, Cassandra M. Hirsch, Amy C Graham, BS, MS, Yasunobu Nagata, Bartlomiej P. Przychodzen, Aziz Nazha, Daniel Lindner, MD PhD, Tomas Radivoyevitch, PhD, James G Phillips, PhD, Jaroslaw P. Maciejewski, Babal K. Jha

Blood (2018) 132 (Supplement 1): 4345.

https://doi.org/10.1182/blood-2018-99-117186

Published: 2018

Journal Articles

Modulation of TET2 Activity By Ascorbic Acid and Factors Affecting Lysine Acetylation

Blood (2018) 132 (Supplement 1): 4346.

https://doi.org/10.1182/blood-2018-99-119712

Published: 2018

Journal Articles

Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML)

Blood (2018) 132 (Supplement 1): 1813.

https://doi.org/10.1182/blood-2018-99-115180

Published: 2018

Journal Articles

Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes

Yazan F. Madanat, MD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MDPhDMPH, Cassandra M. Hirsch, Yihong Guan, Yasunobu Nagata, Vera Adema, PhD, Metis Hasipek, PhD, Aaron T. Gerds, MDMS, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Bartlomiej P. Przychodzen, Valeria Santini, Jaroslaw P. Maciejewski, Babal K. Jha, Aziz Nazha

Blood (2018) 132 (Supplement 1): 1797.

https://doi.org/10.1182/blood-2018-99-114681

Published: 2018

Journal Articles

Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype

Aziz Nazha, Manja Meggendorfer, PhD, Sudipto Mukherjee, MD PhD MPH, Wencke Walter, PhD, Stephan Hutter, PhD, Ahed Makhoul, MD, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Hetty E. Carraway, MD MBA, Yasunobu Nagata, Yihong Guan, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, Jaroslaw P. Maciejewski, Claudia Haferlach, MD, Mikkael A. Sekeres, MD MS, Torsten Haferlach, MD

Blood (2018) 132 (Supplement 1): 2809.

https://doi.org/10.1182/blood-2018-99-114782

Published: 2018

Journal Articles

Therapeutic Targeting of GLI1 in Acute Myeloid Leukemia

Metis Hasipek, PhD, Sayer Al-Harbi, PhD, James G Phillips, PhD, Bartlomiej P. Przychodzen, MSc, Alek Nielsen, BS, Yihong Guan, PhD, Dale Grabowski, BS, Phillip J Maciejewski, Aziz Nazha, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Babal K Jha, PhD

Blood (2017) 130 (Supplement 1): 2654.

https://doi.org/10.1182/blood.V130.Suppl_1.2654.2654

Published: 2017

Journal Articles

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

Xiaorong Gu, PhD, Quteba Ebrahem, MD, Reda Z. Mahfouz, MD PhD, Metis Hasipek, PhD, Francis Enane, PhD, Tomas Radivoyevitch, Nicolas Rapin, PhDMSc, Bartlomiej P. Przychodzen, MSc, Ramesh Balusu, PhD, Claudiu V Cotta, David Wald, MD PhD, Zhenbo Hu, MD PhD, Yosef Landesman, PhD, Maria Paola Martelli, MD PhD, Brunangelo Falini, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Babal K Jha, PhD, Yogenthiran Saunthararajah, MD

Blood (2017) 130 (Supplement 1): 878.

https://doi.org/10.1182/blood.V130.Suppl_1.878.878

Published: 2017

Journal Articles

The GLI-Code As a Potential Therapeutic Target in Myeloid Neoplasms

Sayer Alharbi, PhD, Alek d Nielsen, B.S., Metis Hasipek, PhD, Bartlomiej P Przychodzen, MSc, James G Phillips, PhD, Jaroslaw P Maciejewski, MD PhD FACP, Babal Jha, PhD

Blood (2016) 128 (22): 1655.

https://doi.org/10.1182/blood.V128.22.1655.1655

Published: 2016

NARROW

Role of Oligoadenylate Synthetases in Myeloid Neoplasia

Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

TET2 Inhibitory Effects of Eltrombopag Contribute Its Hematopoietic Activity

A Novel Therapeutic Strategy for Preferential Elimination of Multiple Myeloma Cells By Targeting Protein Disulfide Isomerase

Eltrombopag Creates a Transient Chemical Phenocopy of TET2 Loss of Function That Contributes to Hematopoietic Precursor Expansion

Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)

Fatty Acid Binding Protein FABP5: A Novel Therapeutic Target in Acute Myeloid Leukemia

TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia

Targeting NAD + Modulating Enzymes to Improve HSC Function in Aging and Bone Marrow Failure

Targeting Antagonists of Retinoic Acid Signaling in Acute Myeloid Leukemia

Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia

Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases

Modulation of TET2 Activity By Ascorbic Acid and Factors Affecting Lysine Acetylation

Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML)

Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes

Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype

Therapeutic Targeting of GLI1 in Acute Myeloid Leukemia

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

The GLI-Code As a Potential Therapeutic Target in Myeloid Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only